| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Franco Giubilei, Caterina Calderaro, Giovanni Antonini, Micaela Sepe-Monti, Paolo Tisei, Ercole Brunetti, Francesca Marchione, Brunella Caronti, Francesco E Pontier. Increased lymphocyte dopamine beta-hydroxylase immunoreactivity in Alzheimer's disease: compensatory response to cholinergic deficit? Dementia and geriatric cognitive disorders. vol 18. issue 3-4. 2005-02-16. PMID:15305112. |
here we show a slight decrease in acetylcholinesterase (ache) and a significant increase in dopamine beta-hydroxylase (dbh) immunoreactivity in the pbl of patients with probable alzheimer's disease (ad). |
2005-02-16 |
2023-08-12 |
Not clear |
| Erika Mendelsohn, Michal Rosenthal, Yosef Bohiri, Edith Werber, Moshe Kotler, Rael D Strou. Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living. International clinical psychopharmacology. vol 19. issue 6. 2005-02-15. PMID:15486516. |
because rivastigmine, a reversible acetylcholinesterase inhibitor, appears to delay the progression of alzheimer's disease, it may also improve or delay the cognitive and behavioural disturbances evident in elderly chronic schizophrenia patients with comorbid cognitive decline. |
2005-02-15 |
2023-08-12 |
human |
| Can C Ozbal, William A LaMarr, John R Linton, Donald F Green, Arrin Katz, Thomas B Morrison, Colin J H Brena. High throughput screening via mass spectrometry: a case study using acetylcholinesterase. Assay and drug development technologies. vol 2. issue 4. 2005-02-08. PMID:15357918. |
a mass spectrometry-based assay was developed to identify inhibitors of acetylcholinesterase, an enzyme with clinical importance in alzheimer's disease. |
2005-02-08 |
2023-08-12 |
Not clear |
| Marco Racchi, Michela Mazzucchelli, Emanuela Porrello, Cristina Lanni, Stefano Govon. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacological research. vol 50. issue 4. 2005-02-04. PMID:15304241. |
the therapeutic approach for improving the cognitive function in patients with alzheimer's disease (ad) is mainly based on the potentiation of central cholinergic activity and is achieved clinically by the use of acetylcholinesterase (ache) inhibitors such as tacrine, donepezil, rivastigmine, galantamine and other drugs currently in clinical trials. |
2005-02-04 |
2023-08-12 |
Not clear |
| Beate Schmitt, Tanja Bernhardt, Hans-Juergen Moeller, Isabella Heuser, Lutz Frölic. Combination therapy in Alzheimer's disease: a review of current evidence. CNS drugs. vol 18. issue 13. 2005-02-04. PMID:15521788. |
presently, acetylcholinesterase inhibitors are the first-line drugs in the treatment of alzheimer's disease (ad). |
2005-02-04 |
2023-08-12 |
Not clear |
| Chukwuemeka S Okereke, Louis Kirby, Dinesh Kumar, Edward I Cullen, Raymond D Pratt, William A Hahn. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. British journal of clinical pharmacology. vol 58 Suppl 1. 2005-02-02. PMID:15496222. |
the use of acetylcholinesterase inhibitors for the treatment of comorbid alzheimer's disease in parkinson's disease (pd) patients stabilized on a levodopa regimen may potentially disrupt cholinergic balance. |
2005-02-02 |
2023-08-12 |
Not clear |
| Peter J Houghton, Joseph M Agbedahunsi, Aderonke Adegbulugb. Choline esterase inhibitory properties of alkaloids from two Nigerian Crinum species. Phytochemistry. vol 65. issue 21. 2005-01-14. PMID:15501257. |
alkaloidal extracts of bulbs from each species showed inhibition of acetylcholinesterase, an activity exploited therapeutically to raise the depressed levels of acetylcholine in the brain associated with alzheimer's disease. |
2005-01-14 |
2023-08-12 |
Not clear |
| Silvia Di Angelantonio, Giorgio Bernardi, Nicola B Mercur. Methamidophos transiently inhibits neuronal nicotinic receptors of rat substantia nigra dopaminergic neurons via open channel block. Neuroscience letters. vol 369. issue 3. 2005-01-13. PMID:15464266. |
the use of acetylcholinesterase (ache) inhibitors is the primary therapeutic strategy in the treatment of alzheimer's disease. |
2005-01-13 |
2023-08-12 |
rat |
| Makoto Tanaka, Chihiro Namiki, Dinh Ha Duy Thuy, Hidefumi Yoshida, Keiichi Kawasaki, Kazuo Hashikawa, Hidenao Fukuyama, Toru Kit. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease. Journal of the neurological sciences. vol 225. issue 1-2. 2005-01-10. PMID:15465097. |
donepezil is a selective acetylcholinesterase inhibitor approved for the symptomatic treatment of mild to moderate alzheimer's disease (ad). |
2005-01-10 |
2023-08-12 |
Not clear |
| Sompop Bencharit, Christopher L Morton, Janice L Hyatt, Peter Kuhn, Mary K Danks, Philip M Potter, Matthew R Redinb. Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. Chemistry & biology. vol 10. issue 4. 2005-01-05. PMID:12725862. |
we determined the 2.4 a crystal structure of hce1 in complex with tacrine, the first drug approved for treating alzheimer's disease, and compare this structure to the torpedo californica acetylcholinesterase (acche)-tacrine complex. |
2005-01-05 |
2023-08-12 |
human |
| Maria Laura Bolognesi, Manuela Bartolini, Andrea Cavalli, Vincenza Andrisano, Michela Rosini, Anna Minarini, Carlo Melchiorr. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. Journal of medicinal chemistry. vol 47. issue 24. 2005-01-03. PMID:15537349. |
rivastigmine (1), an acetylcholinesterase (ache) inhibitor approved in 2000 for the treatment of alzheimer disease, bears a carbamate moiety in its structure, which is able to react covalently with the active site of the enzyme. |
2005-01-03 |
2023-08-12 |
human |
| R Perneczky, A Kur. [Current antidementive therapy]. MMW Fortschritte der Medizin. vol 146 Spec No 2. 2004-12-22. PMID:15376702. |
the acetylcholinesterase inhibitors, donepezil, galantamine and rivastigmine have been approved for the treatment of mild-to-moderate alzheimer's dementia, the nmda inhibitor memantine is approved for moderate-to-severe alzheimer's disease. |
2004-12-22 |
2023-08-12 |
Not clear |
| Sang-Yoon Lee, Yearn Seong Choe, Yu Ri Kim, Jin-Young Paik, Byoung Wook Choi, Sang Eun Kim, Kyung-Han Lee, Yong Choi, Byung-Tae Ki. Synthesis and evaluation of 5,7-dihydro-3-[2-[1-(4-[18F]-fluorobenzyl)-4-piperidinyl]ethyl]-6H-pyrrolo[3,2-f]-1,2-benzisoxazol-6-one for in vivo mapping of acetylcholinesterase. Nuclear medicine communications. vol 25. issue 6. 2004-12-20. PMID:15167519. |
acetylcholinesterase (ache) is an important cholinergic marker for the diagnosis of alzheimer's disease (ad). |
2004-12-20 |
2023-08-12 |
Not clear |
| Edward J Okello, Sergey U Savelev, Elaine K Perr. In vitro anti-beta-secretase and dual anti-cholinesterase activities of Camellia sinensis L. (tea) relevant to treatment of dementia. Phytotherapy research : PTR. vol 18. issue 8. 2004-12-02. PMID:15476306. |
the primary target of licensed drugs for the treatment of alzheimer's disease is the inhibition of the enzyme acetylcholinesterase, although preventing beta-amyloidosis is a prime target for drugs in development. |
2004-12-02 |
2023-08-12 |
human |
| J O Rinne, V Kaasinen, T Järvenpää, K Någren, A Roivainen, M Yu, V Oikonen, T Kurk. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. Journal of neurology, neurosurgery, and psychiatry. vol 74. issue 1. 2004-11-16. PMID:12486280. |
brain acetylcholinesterase activity in mild cognitive impairment and early alzheimer's disease. |
2004-11-16 |
2023-08-12 |
Not clear |
| J O Rinne, V Kaasinen, T Järvenpää, K Någren, A Roivainen, M Yu, V Oikonen, T Kurk. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. Journal of neurology, neurosurgery, and psychiatry. vol 74. issue 1. 2004-11-16. PMID:12486280. |
brain acetylcholinesterase activity was determined in healthy controls and in patients with mild cognitive impairment and early alzheimer's disease. |
2004-11-16 |
2023-08-12 |
Not clear |
| Lifen Zhang, Fu-Ming Zhou, John A Dan. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Molecular pharmacology. vol 66. issue 3. 2004-11-03. PMID:15322245. |
the most commonly prescribed treatments for alzheimer's disease are acetylcholinesterase inhibitors, such as donepezil and galantamine. |
2004-11-03 |
2023-08-12 |
mouse |
| Shigeki Moriguchi, William Marszalec, Xilong Zhao, Jay Z Yeh, Toshio Narahash. Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons. The Journal of pharmacology and experimental therapeutics. vol 310. issue 3. 2004-11-01. PMID:15121761. |
galantamine, a new alzheimer's drug approved in the united states, is known to inhibit acetylcholinesterase and potentiate acetylcholine-induced currents in brain neurons. |
2004-11-01 |
2023-08-12 |
rat |
| b' A V Veselovski\\xc4\\xa. [Dual monoaminoxidase and acetylcholinesterase inhibitors as potential agents for treatment of Alzheimer disease]. Biomeditsinskaia khimiia. vol 50. issue 3. 2004-10-28. PMID:15354544.' |
[dual monoaminoxidase and acetylcholinesterase inhibitors as potential agents for treatment of alzheimer disease]. |
2004-10-28 |
2023-08-12 |
Not clear |
| Martina Zimmermann, Fabrizio Gardoni, Elena Marcello, Francesca Colciaghi, Barbara Borroni, Alessandro Padovani, Flaminio Cattabeni, Monica Di Luc. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. Journal of neurochemistry. vol 90. issue 6. 2004-10-27. PMID:15341532. |
acetylcholinesterase inhibitors (acheis) are the only currently available drugs for treating alzheimer's disease (ad). |
2004-10-27 |
2023-08-12 |
human |